NAPLEX Flashcards: Emergency Use Authorizations

What this deck covers

This deck focuses on Emergency Use Authorizations, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.

How to use these flashcards

Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.

Flashcard 1: What is the key operational takeaway for dispensing an EUA product in practice?

Answer: Dispense/administer only per LOA and provide the required EUA fact sheet. Adhering to LOA and distributing fact sheets ensures compliance with EUA legal requirements for pharmacists.

Flashcard 2: What is the third core statutory criterion for an EUA besides effectiveness and benefit-risk?

Answer: No adequate, approved, and available alternative exists. This criterion ensures EUA is used only when no other suitable options meet the emergency needs under section 564.

Flashcard 3: What must recipients be told about the option to accept or refuse an EUA product?

Answer: They have the option to accept or refuse the product. EUA statute mandates informing potential recipients of their right to choose, promoting voluntary use.

Flashcard 4: What must recipients be told about available alternatives to an EUA product?

Answer: Information on alternatives and their risks and benefits. EUA requires communicating alternatives to enable informed choices about the emergency-authorized product.

Flashcard 5: What is the primary counseling point that distinguishes an EUA product from an approved product?

Answer: It is authorized for emergency use and may have limited data compared with approval. This highlights the provisional nature of EUA, informing patients of potential uncertainties versus fully approved products.

Flashcard 6: Which FDA document communicates an EUA product's authorized conditions and directions?

Answer: The EUA Letter of Authorization (LOA). The LOA issued by FDA specifies the scope, conditions, and requirements for the product's emergency use.

Flashcard 7: What is the required benefit-risk conclusion FDA must reach to issue an EUA?

Answer: Known and potential benefits outweigh known and potential risks. FDA must conclude that benefits of the product outweigh risks for the intended use in the emergency context to issue an EUA.

Flashcard 8: What does an FDA Emergency Use Authorization (EUA) permit for a medical product?

Answer: Use of an unapproved product or unapproved use during an emergency. EUA allows temporary use of medical countermeasures lacking full approval to address public health emergencies when criteria are met.

Flashcard 9: Which federal official must declare an emergency to enable FDA to issue EUAs under section 564?

Answer: The HHS Secretary (after a relevant emergency determination). Under FD&C Act section 564, the HHS Secretary's declaration of an emergency or threat is required to trigger FDA's EUA authority.

Flashcard 10: What document must be provided to recipients for an EUA vaccine or drug to describe key information?

Answer: The EUA Fact Sheet for Recipients and Caregivers. This fact sheet informs recipients about the product's benefits, risks, and right to refuse under EUA requirements.

Flashcard 11: What does the EUA criterion "no adequate, approved, and available alternative" mean in practice?

Answer: An approved option may exist but is not adequate or not available in time/quantity. The criterion allows EUA even if approved products exist, if they are insufficient in efficacy, supply, or accessibility for the emergency.

Flashcard 12: What is the difference between an EUA and an IND in terms of purpose?

Answer: EUA authorizes emergency use; IND enables investigational use in trials/expanded access. EUA facilitates broad distribution in emergencies, while IND regulates controlled investigational settings.

Flashcard 13: Identify the correct storage/handling reference for an EUA product when policies conflict: LOA, label, or fact sheet?

Answer: Follow the LOA and EUA fact sheets; they define the authorized conditions. LOA and fact sheets supersede other sources as they outline the specific emergency authorization terms.

Flashcard 14: What is a common EUA condition related to adverse event monitoring and reporting?

Answer: Required adverse event reporting (often to FDA/CDC systems as specified). EUAs often mandate reporting to monitor safety and effectiveness during widespread emergency use.

Flashcard 15: Which option is correct: EUA products can be used outside authorized conditions without restrictions, yes or no?

Answer: No; use must follow the authorized conditions unless otherwise permitted by law/policy. EUA limits use to specified conditions to maintain safety and efficacy in emergency settings.

Flashcard 16: What is the legal status of an EUA product regarding FDA approval?

Answer: Authorized for emergency use; not FDA-approved for that use. EUA provides temporary authorization for emergency circumstances but does not confer full FDA approval status or standards.

Flashcard 17: What is the pharmacist's best first step to confirm whether a use is covered by an EUA?

Answer: Verify the authorized indication, population, and directions in the LOA/fact sheet. Checking official EUA documents ensures the proposed use aligns with FDA's authorized parameters.

Flashcard 18: Identify the correct statement about EUA labeling: does it use standard FDA-approved package insert, yes or no?

Answer: No; EUA uses fact sheets and LOA-defined labeling elements. EUA products lack standard labeling; fact sheets and LOA provide necessary information instead.

Flashcard 19: What document must be provided to health care providers for an EUA product?

Answer: The EUA Fact Sheet for Health Care Providers. This fact sheet provides providers with dosing, administration, and safety information required for EUA compliance.

Flashcard 20: Which statement is correct: an EUA requires informed consent like a clinical trial, yes or no?

Answer: No; it requires specific recipient information, not clinical-trial informed consent. EUA focuses on providing key information via fact sheets rather than formal consent processes used in clinical trials.

Flashcard 21: What happens to EUA authorization when the underlying emergency declaration ends?

Answer: The EUA may be terminated or revoked and is no longer in effect. The EUA's validity depends on the active emergency declaration, leading to termination when it expires.

Flashcard 22: What must recipients be told about the consequences of refusing an EUA product?

Answer: Any known consequences of refusing must be disclosed. Disclosure of refusal consequences ensures transparency and informed decision-making as per EUA information requirements.

Flashcard 23: Which option best describes FDA's authority under an EUA regarding distribution controls?

Answer: FDA may impose conditions on distribution, administration, and monitoring. Section 564 grants FDA flexibility to set controls ensuring safe and effective emergency deployment.

Flashcard 24: What is the key evidentiary standard for effectiveness in an EUA compared with full approval?

Answer: May be effective (lower than the substantial evidence standard). EUA requires only that the product 'may be effective' based on totality of scientific evidence, unlike the higher 'substantial evidence' for full approval.

Flashcard 25: What does it mean when an EUA is revised or reissued by FDA?

Answer: Authorized conditions (e.g., dosing, population, warnings) have been updated. Revisions reflect new data or circumstances, updating the authorization to ensure ongoing appropriateness.